Nanotechnology integrated into such devices comes at a cost. The base cost of the actual electronic cradle device is very expensive and has been designed for low spread distribution single point test model scenarios ie roadside, diagnostics, hospitals and test laboratories etc. Unless production and development costs fall dramatically, nanotechnology is unlikely to find a place in the more generic testing regimes of the workplace, entertainment and school testing programs that incidentally, represent the primary targets for SBN.
Cheers
- Forums
- ASX - By Stock
- interesting article
Nanotechnology integrated into such devices comes at a cost. The...
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SBN (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online